eli lilly

Eli Lilly and Company (LLY) is a leading player in the pharmaceutical industry, known for its innovative medications and strategic expansions. Here's a comprehensive analysis of LLY's current market position and future outlook: 1. **Technical Indicators Suggest Caution**: The closing price of LLY on April 16, 2025, was $734.9, with resistance at $765.31 and support at $691.77. The MACD is negative at -5.5, indicating potential bearish momentum, while the RSI is at 38.21, suggesting the stock is neither overbought nor oversold. The 5-day, 10-day, and 20-day moving averages are $739.95, $743.07, and $787.42, respectively, with the stock trading below these averages, which could be a bearish signal. |code|Ticker|Name|Date|Closing Price|Support Level|Resistance Level|market_code| |---|---|---|---|---|---|---|---| |LLY|LLY.N|Eli Lilly|20250416|734.9|730.3400|756.3000|169| |code|Ticker|Name|Date|RSI|KDJ|MACD|market_code| |---|---|---|---|---|---|---|---| |LLY|LLY.N|Eli Lilly|20250416|38.2136|70.4611|-5.4964|169| |code|Ticker|Name|Date|Moving Average|market_code| |---|---|---|---|---|---| |LLY|LLY.N|Eli Lilly|20250416|739.9500|169| 2. **Fund Flow Shows Weakness**: There was a net fund outflow of $44.12 million, with block order outflows of $40.08 million, which could indicate investor uncertainty or a lack of confidence in the stock's short-term performance. |code|Ticker|Name|Date|Net Fund Flow|Net Fund Flow (Block Order)|market_code| |---|---|---|---|---|---|---| |LLY|LLY.N|Eli Lilly|20250106|-1.207483532519E8|-1.126747514276E8|169| |LLY|LLY.N|Eli Lilly|20250107|1.7406445443E7|1.5130564032E7|169| |LLY|LLY.N|Eli Lilly|20250108|2.20306308579E7|1.35386228365E7|169| |LLY|LLY.N|Eli Lilly|20250110|7.46284422393E7|6.67090089285E7|169| |LLY|LLY.N|Eli Lilly|20250113|-7.17250830252E7|-7.26863722419E7|169| |LLY|LLY.N|Eli Lilly|20250114|-3.846937693016E8|-3.710964710892E8|169| |LLY|LLY.N|Eli Lilly|20250115|-1.47450091452E8|-1.412939646012E8|169| |LLY|LLY.N|Eli Lilly|20250116|-9754689.5425|-1.28582348261E7|169| |LLY|LLY.N|Eli Lilly|20250117|-2.786125642123E8|-2.629224015492E8|169| |LLY|LLY.N|Eli Lilly|20250121|-3.97801314651E7|-3.77638643226E7|169| 3. **Analysts Hold a Positive Outlook**: The average price target from analysts is $1034, with a consensus rating of "Strong Buy". This suggests that analysts believe the stock has room to grow from its current price. 4. **Valuation Metrics Show Premium**: With a P/E ratio of 65.79, a P/S ratio of 15.47, and a Price to Book Ratio of 49.09, LLY is trading at a premium compared to some peers, which could be due to its strong growth prospects and dominant position in the weight loss drug market. |code|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio|market_code| |---|---|---|---|---|---|---|---| |LLY|LLY.N|Eli Lilly|20240417|116.285691|0|66.26562304672342|169| |LLY|LLY.N|Eli Lilly|20240418|115.539129|0|65.8401927510467|169| |LLY|LLY.N|Eli Lilly|20240419|112.497117|0|64.10669669148433|169| |LLY|LLY.N|Eli Lilly|20240422|113.274658|0|64.54977969652522|169| |LLY|LLY.N|Eli Lilly|20240423|115.498857|0|65.81724422887328|169| |LLY|LLY.N|Eli Lilly|20240424|113.409411|0|64.6265689822594|169| |LLY|LLY.N|Eli Lilly|20240425|112.231257|0|63.979597184062236|169| |LLY|LLY.N|Eli Lilly|20240426|113.568984|0|64.74219422859477|169| |LLY|LLY.N|Eli Lilly|20240429|114.140305|0|65.06788671636387|169| |LLY|LLY.N|Eli Lilly|20240430|120.93732|0|57.94177791515899|169| 5. **Legal Challenges and Strategic Moves**: LLY has initiated legal action against OrderlyMeds over a compounded version of its product, tirzepatide. This strategic move could be a sign of the company's defensive stance in the face of competition and its commitment to protecting its intellectual property. 6. **Manufacturing Expansion and Revenue Growth**: LLY is investing $50 billion in its U.S. manufacturing capacity, a move that analysts see as a positive sign for the company's future growth. The company has also seen a 32% increase in revenue for 2024, driven by strong demand for key drugs. 7. **New Product Pipeline**: The company's new oral weight loss pill, orforglipron, has shown promising results in a Phase 3 trial, pushing shares up by 11%. This could be a significant catalyst for the stock in the coming months. In conclusion, while there are some technical indicators that suggest caution, the overall outlook for Eli Lilly is positive, with analysts holding a bullish view and the company making strategic moves to strengthen its market position and expand its manufacturing capabilities. The introduction of new products and the growth in revenue provide a solid foundation for future growth.